1. Generics Bulletin
  2. >>Business
  3. >>Strategy

The View From The Top: European CEOs Highlight Industry Priorities

Leaders Discuss Concerns And Opportunities For The European Generics And Biosimilars Sector

 
• By Dave Wallace

At a high-profile panel closing out Medicines for Europe’s 30th annual conference in Dublin, six industry leaders set out their views on key topics including pricing, regulation, sustainability, and stakeholder communication.

CEOs panel at Medicines for Europe annual conference
(L-R) Pierluigi Antonelli, Markus Sieger, Elisabeth Stampa, Rebecca Guntern, Stephan Eder and Steffen Saltofte address Medicines for Europe’s annual conference • Source: Medicines for Europe

Medicines for Europe’s 30th annual conference in Dublin earlier this month saw a packed house for its concluding panel, which brought together six leading executives from top European off-patent industry players to dissect the key challenges and opportunities facing the generics and biosimilars industry today.

The six leaders comprised Pierluigi Antonelli, president and CEO of Fresenius Kabi; Markus Sieger, CEO of Polpharma Group; Elisabeth Stampa, president of Medicines for Europe and board member at Medichem; Rebecca Guntern, Sandoz’s president for Europe; Stephan Eder, executive vice president for

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.

UK-India FTA Could Offer ‘Significant Benefits’ For Generics And Biosimilars

 
• By Dave Wallace

A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.

Teva’s Uzedy Continues Surge As Olanzapine LAI Filing Nudges Closer

 
• By Dean Rudge

Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.

More from Conferences

IGBA’s Susana Almeida On Consensus Building, Harmonization, And Policy Built On Science – Not Politics

 
• By Urtė Fultinavičiūtė

IGBA secretary general Susana Almeida takes Generics Bulletin through an almost two-decade journey of developing global regulatory convergence and the next goals for the off-patent industry.

After A Decade Of US Biosimilars, ‘The Challenges Are Becoming More Clear’

 
• By Dave Wallace

As the US marks 10 years since the first biosimilar approval and launch, AAM Biosimilars Council executive director Craig Burton talks to Generics Bulletin about the lessons learned so far and the path ahead, including how to move on from market models that have proved to be “not appropriate” for biosimilars.

In Discussion With Medicines For Europe: Bracing For US Tariffs And Embracing Ukraine

 
• By Urtė Fultinavičiūtė

Tariffs, international cooperation, and war: the off-patent industry is not immune to the political issues raging across the globe. Medicines for Europe’s Adrian van den Hoven and Beata Stepniewska spoke with Generics Bulletin about what these developments mean for the sector.